Last reviewed · How we verify
TG-1501
At a glance
| Generic name | TG-1501 |
|---|---|
| Sponsor | TG Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation (PHASE1)
- Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TG-1501 CI brief — competitive landscape report
- TG-1501 updates RSS · CI watch RSS
- TG Therapeutics, Inc. portfolio CI